We are live on ! Find out more
INDV icon

Indivior Pharmaceuticals

76 hedge funds and large institutions have $1.04B invested in Indivior Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

4% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 26

0% more funds holding

Funds holding: 7676 (0)

2.47% less ownership

Funds ownership: 49.41%46.94% (-2.5%)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

46% less capital invested

Capital invested by funds: $1.91B → $1.04B (-$876M)

Holders
76
Holders Change
Holders Change %
0%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
7
Increased
27
Reduced
26
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
IA
76
IFP Advisors
Florida
$15
PCH
77
Polar Capital Holdings
United Kingdom
-$60.5M -2,621,150 Closed
Capital World Investors
78
Capital World Investors
California
-$27.8M -1,284,920 Closed
PAMP
79
Polar Asset Management Partners
Ontario, Canada
-$3.52M -161,900 Closed
MGIM
80
M&G Investment Management
United Kingdom
-$71.7M -33,058 Closed
CSPIA
81
Cary Street Partners Investment Advisory
Virginia
-$4.61K -200 Closed
M
82
MOTCO
Texas
-$2.05K -89 Closed

INDV Hedge Fund Activity: Q4 2023 in Review

76 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q4 2023, worth a combined $1.04B — down 46% from $1.91B a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new INDV positions and 6 closed out — a net gain of 1 holder — while 27 added to existing stakes and 26 trimmed.

The largest buyer was Barclays, adding an estimated $48.4M. The largest seller was M&G Investment Management, exiting entirely with an estimated $71.7M sold.

  • 76 institutional investors held Indivior Pharmaceuticals (INDV) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $1.04B of Indivior Pharmaceuticals stock for Q4 2023, down 46% quarter-over-quarter.
  • 7 funds opened new Indivior Pharmaceuticals positions in Q4 2023 and 6 closed out, a net change of +1 holder.
  • The largest Indivior Pharmaceuticals buyer in Q4 2023 was Barclays, an estimated $48.4M added.
  • The largest Indivior Pharmaceuticals seller in Q4 2023 was M&G Investment Management, an estimated $71.7M sold.

Based on aggregated 13F filings for Q4 2023.